OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 4, pp. 310-322
Closed Access | Times Cited: 32
Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 4, pp. 310-322
Closed Access | Times Cited: 32
Showing 1-25 of 32 citing articles:
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Arndt Vogel, S.L. Chan, Laura A. Dawson, et al.
Annals of Oncology (2025)
Closed Access | Times Cited: 2
Arndt Vogel, S.L. Chan, Laura A. Dawson, et al.
Annals of Oncology (2025)
Closed Access | Times Cited: 2
Advances in Immunotherapy in Hepatocellular Carcinoma
Matthew B. Bloom, S. Podder, Hien Dang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 1936-1936
Open Access | Times Cited: 2
Matthew B. Bloom, S. Podder, Hien Dang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 1936-1936
Open Access | Times Cited: 2
Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide
Vishnu Nagalapuram, Niveditha Popuri, Ryan David Nipp, et al.
JCO Oncology Practice (2025)
Closed Access | Times Cited: 2
Vishnu Nagalapuram, Niveditha Popuri, Ryan David Nipp, et al.
JCO Oncology Practice (2025)
Closed Access | Times Cited: 2
MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options
Yuming Shi, Erfan Taherifard, A.I. Saeed, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 6, pp. 5965-5983
Open Access | Times Cited: 7
Yuming Shi, Erfan Taherifard, A.I. Saeed, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 6, pp. 5965-5983
Open Access | Times Cited: 7
The current status and future of targeted-immune combination for hepatocellular carcinoma
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Liyuan Hao, Shenghao Li, Fanghang Ye, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies
Simona Gurzu, Rita Szodorai, Ioan Jung, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access | Times Cited: 6
Simona Gurzu, Rita Szodorai, Ioan Jung, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access | Times Cited: 6
Treatment for hepatocellular carcinoma after immunotherapy
Landon L. Chan, Tsz Tung Kwong, Jonathan Yau, et al.
Annals of Hepatology (2025), pp. 101781-101781
Open Access
Landon L. Chan, Tsz Tung Kwong, Jonathan Yau, et al.
Annals of Hepatology (2025), pp. 101781-101781
Open Access
Real-world insights into cabozantinib efficacy in hepatocellular carcinoma
Kuan-Chang Lai, Te-Lin Hsu, Shih-Yao Lin, et al.
Annals of Hepatology (2025), pp. 101917-101917
Open Access
Kuan-Chang Lai, Te-Lin Hsu, Shih-Yao Lin, et al.
Annals of Hepatology (2025), pp. 101917-101917
Open Access
Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinoma
Xiangbo Huang, Nan Yi, Pengfei Zhu, et al.
Biology Direct (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 3
Xiangbo Huang, Nan Yi, Pengfei Zhu, et al.
Biology Direct (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 3
Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma
Kyoko Oura, Asahiro Morishita, Tomoko Tadokoro, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13590-13590
Open Access | Times Cited: 3
Kyoko Oura, Asahiro Morishita, Tomoko Tadokoro, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13590-13590
Open Access | Times Cited: 3
Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma: a meta-analysis and trial sequential analysis of randomized controlled trials
Peng Tang, Fei Zhou
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Peng Tang, Fei Zhou
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Qibin Wu, Xia Zhao, Chong Yang, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104730-104730
Closed Access
Qibin Wu, Xia Zhao, Chong Yang, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104730-104730
Closed Access
Targeting angiogenesis in gastrointestinal tumors: strategies from vascular disruption to vascular normalization and promotion strategies angiogenesis strategies in GI tumor therapy
Jiajia Li, Zhengrui Li, Keliang Wang
Frontiers in Immunology (2025) Vol. 16
Open Access
Jiajia Li, Zhengrui Li, Keliang Wang
Frontiers in Immunology (2025) Vol. 16
Open Access
Of mice and men: Unlocking precision medicine for liver cancer
David J. Pinato
Journal of Hepatology (2025)
Closed Access
David J. Pinato
Journal of Hepatology (2025)
Closed Access
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Weixin Wang, Xin Gao, Wei Niu, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 9, pp. 4077-4077
Open Access
Weixin Wang, Xin Gao, Wei Niu, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 9, pp. 4077-4077
Open Access
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
Jian Zhou, Li Bai, Jia Luo, et al.
The Lancet Oncology (2025)
Closed Access
Jian Zhou, Li Bai, Jia Luo, et al.
The Lancet Oncology (2025)
Closed Access
Immunotherapy plus tyrosine-kinase inhibitors in hepatocellular carcinoma
Antonella Cammarota, Lorenza Rimassa
The Lancet Oncology (2025)
Closed Access
Antonella Cammarota, Lorenza Rimassa
The Lancet Oncology (2025)
Closed Access
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Thomas Yau, Peter R. Galle, Thomas Decaens, et al.
The Lancet (2025)
Open Access
Thomas Yau, Peter R. Galle, Thomas Decaens, et al.
The Lancet (2025)
Open Access
The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers
Giuseppe Cabibbo, Lorenza Rimassa, Ángela Lamarca, et al.
Cancer Treatment Reviews (2025), pp. 102955-102955
Open Access
Giuseppe Cabibbo, Lorenza Rimassa, Ángela Lamarca, et al.
Cancer Treatment Reviews (2025), pp. 102955-102955
Open Access
Treatment options for advanced hepatocellular carcinoma: the potential of biologics
Federico Rossari, Silvia Foti, Silvia Camera, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 6, pp. 455-470
Closed Access | Times Cited: 2
Federico Rossari, Silvia Foti, Silvia Camera, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 6, pp. 455-470
Closed Access | Times Cited: 2
Current Treatment Methods in Hepatocellular Carcinoma
Katherine Krupa, Marta Fudalej, Anna Cencelewicz-Lesikow, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4059-4059
Open Access | Times Cited: 2
Katherine Krupa, Marta Fudalej, Anna Cencelewicz-Lesikow, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4059-4059
Open Access | Times Cited: 2
Targeted therapies in hepatocellular carcinoma: past, present, and future
Rushabh Gujarathi, Joseph W. Franses, Anjana Pillai, et al.
Frontiers in Oncology (2024) Vol. 14
Closed Access | Times Cited: 1
Rushabh Gujarathi, Joseph W. Franses, Anjana Pillai, et al.
Frontiers in Oncology (2024) Vol. 14
Closed Access | Times Cited: 1
Hepatocellular carcinoma systemic treatment 2024 update: from early to advanced stage
Wei Teng, T-H Wu, Shi‐Ming Lin
Biomedical Journal (2024), pp. 100815-100815
Open Access | Times Cited: 1
Wei Teng, T-H Wu, Shi‐Ming Lin
Biomedical Journal (2024), pp. 100815-100815
Open Access | Times Cited: 1
Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors
Yong Zhou, Zhengcheng Liu, Ao Yu, et al.
ImmunoTargets and Therapy (2024) Vol. Volume 13, pp. 813-829
Open Access | Times Cited: 1
Yong Zhou, Zhengcheng Liu, Ao Yu, et al.
ImmunoTargets and Therapy (2024) Vol. Volume 13, pp. 813-829
Open Access | Times Cited: 1
